{"type":"trials","record":{"id":41976,"source_id":"clinicaltrials-gov","external_id":"NCT04662944","title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","brief_summary":"RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD patients treated with licensed anti-VEGFs","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":494,"countries":["Canada","Germany","Ireland","Italy","Spain"],"start_date":"2021-02-23","completion_date":"2023-06-28","last_update_date":"2024-06-18","source_url":"https://clinicaltrials.gov/study/NCT04662944","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"RAZORBILL","age_range":"18 Years to 199 Years","comparator":null,"organization":"Novartis","interventions":["brolucizumab","ranibizumab","aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Odds ratio of disease activity assessment from Optical Coherence Tomography (OCTs) with and without enrichment — 12 mon…","Degree of agreement in classification of disease activity using enriched and non-enriched OCT images — 12 months","Difference in time needed for Disease Activity Assessment (DAA) between reviews with and without enrichment — 12 months","Difference in confidence in DAA between reviews with and without enrichment — 12 months","Acceptance of Discovery by physicians and whether it can optimize the ophthalmic clinical workflow — Month 12","Percentage of patients with absence of Subretinal Fluid, Intraretinal Fluid and Pigment Epithelium Detachment — Month 12","Central Subfield Thickness (CST) change — 12 months","Best-corrected visual acuity change from baseline — 12 months","Percentage of patients with ocular and non-ocular adverse events — 12 months","Subjective assessment of system correctness — 12 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration","brolucizumab","ranibizumab","aflibercept"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04662944","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-02-23 to 2023-06-28","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 199 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.902Z","intervention":["brolucizumab","ranibizumab","aflibercept"],"participants":494,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Odds ratio of disease activity assessment from Optical Coherence Tomography (OCTs) with and without enrichment — 12 mon…","Degree of agreement in classification of disease activity using enriched and non-enriched OCT images — 12 months","Difference in time needed for Disease Activity Assessment (DAA) between reviews with and without enrichment — 12 months","Difference in confidence in DAA between reviews with and without enrichment — 12 months","Acceptance of Discovery by physicians and whether it can optimize the ophthalmic clinical workflow — Month 12","Percentage of patients with absence of Subretinal Fluid, Intraretinal Fluid and Pigment Epithelium Detachment — Month 12","Central Subfield Thickness (CST) change — 12 months","Best-corrected visual acuity change from baseline — 12 months","Percentage of patients with ocular and non-ocular adverse events — 12 months","Subjective assessment of system correctness — 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41976","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}